Embecta Corp. (NASDAQ: EMBC) has announced changes to its board of directors, with David J. Albritton resigning from the board due to personal reasons, and LTG (Ret.) David F. Melcher deciding not to stand for re-election at Embecta's 2026 annual stockholder meeting and retiring from the board at that time. Both individuals have been directors since the board's inception in 2022.
Devdatt "Dev" Kurdikar, President and CEO of Embecta, expressed gratitude for the valuable leadership experience both Albritton and Melcher provided during the company's transition phase. Kurdikar specifically thanked Albritton for his contributions in shaping Embecta's corporate identity and communications efforts, while acknowledging Melcher's leadership and mentoring, stating that his counsel and support were integral to the company's execution of multiple complex initiatives.
Upon LTG Melcher's departure, the board intends to appoint Mr. Kurdikar as chairman and Dr. Claire Pomeroy, who has served on the board since its inception, as lead independent director. The corporate governance and nominating committee will assess the expertise desired from future independent directors in light of the company's strategic direction and recommend potential replacements for the departing directors.
Embecta, a global company with approximately 2,000 employees worldwide, is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, aiming to improve lives through innovative solutions and partnerships. Today the company's shares have moved -1.65% to a price of $14.31. For more information, read the company's full 8-K submission here.
